Abstract:OBJECTIVE:To study the anti-tumor angiogenesis effect of soluble VEGF receptor fragment by blocking the combination of VEGF and its receptor in vivo and in vitro.METHODS:RT-PCR technique was used to amplify Flk-1/KDR fragment from embryo mouse liver, which was recombinated to expression vector pET-28b(+) and retrovirus vector PLXSN, which was induced to be expressed, purified and identified with EcoR I and Hind III. Mouse endothelial cells were separated, cultured and identified by immunocytochemistrical staining using VIII factor-related antigen antibody. The expressed product was analyzed about its effect on endothelial cell's growth in vitro with MTT method. The retrovirus vector was transfected to tumor cell lines S180 and B16 by liposome method to observe the biological specificity in vitro after gene transfection.RESULTS:1000 bp size sVEGFR fragment was amplify from E9, E11 embryo mouse liver tissues, which was recombinated to TA clone vector and identified by sequence analysis. This fragment was cloned to expression vector pET-28b(+), the expressed product was purified and identified correctly. The in vitro study showed this expressed product can effectively inhibit endothelial cell(s), growth and proliferation. The fragment was then cloned to retrovirus vector PLXSN and transfected to tumor cell lines S180 and B16 successfully with RT-PCR and SDS-PAGE. The experiments in vivo showed that the weight of tumor smaller, the size decreased significantly, the microvessel density was fewer and Flk1 protein expression were higher in the group of gene transfection than that of control.CONCLUSION:Soluble VEGFR fragment is a kind of effective gene engineer product for anti-tumor angiogenesis gene therapy and the development of anti-tumor drug.

Construction and Application of Cell-Based Models for Screening Vascular Endothelial Growth Factor Receptor-2 Inhibitors

Construction and Application of Cell-Based Models for Screening PDGFR-β Inhibitors

Expression and purification of the catalytic domain of human vascular endothelial growth factor receptor 2 for inhibitor screening.

Expression and purification of human vascular-endothelial-growth-factor-receptor-2 tyrosine kinase in Streptomyces for inhibitor screening.

3D physiologically-informed deep learning for drug discovery of a novel vascular endothelial growth factor receptor-2 (VEGFR2)

A Combination of 2D Similarity Search, Pharmacophore, and Molecular Docking Techniques for the Identification of Vascular Endothelial Growth Factor Receptor-2 Inhibitors

[Cloning, Expression of Soluble VEGFR2 Fragment and Its Effect on Tumor Angiogenesis].

Soluble Expression and Purification of the Catalytic Domain of Human Vascular Endothelial Growth Factor Receptor 2 in Escherichia Coli

Novel VEGFR2 targeted inhibitors:screening and detection of anti-tumor biological properties

Gene Cloning of Soluble VEGF Receptor FLT-1 and the Effect of Its Recombinant Protein on Angiogenesis

Molecular Modeling Studies of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Combining Molecular Docking and 3D-Qsar Methods

Preparation and Application of Modified VEGFR-2 Cell Membrane Chromatographic Separation System

Identification Of Vegfr2-Binding Peptides Using High Throughput Bacterial Display Methods And Functional Assessment

In Silico Screening of 1,3,4-Thiadiazole Derivatives as Inhibitors of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2)

Expression of Soluble Vascular Endothelial Growth Factor Receptor-2 and Its Effect on Proliferation of Vascular Endothelial Cells

Discovering Small Molecule Ligands of Vascular Endothelial Growth Factor That Block Vegf-Kdr Binding Using Label-Free Microarray-Based Assays

Molecular Modeling Studies of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Using QSAR and Docking.

Establishment and Application of High Throughput Screening Model for Kinase Insert Domain Receptor

Discovery of VEGFR2 inhibitors by integrating naïve Bayesian classification, molecular docking and drug screening approaches

Construction,Expression and Biological Activity Studies of a Bivalent Single Chain Variable Fragment (BsFv)against Vascular Endothelial Growth Factor Receptor 2

Discovery of a Highly Selective VEGFR2 Kinase Inhibitor CHMFL-VEGFR2-002 As a Novel Anti-Angiogenesis Agent